These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15111005)

  • 21. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
    Olazarán J; García G
    Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study.
    Canevelli M; Adali N; Kelaiditi E; Cantet C; Ousset PJ; Cesari M;
    Phytomedicine; 2014 May; 21(6):888-92. PubMed ID: 24548724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New therapeutic options in Alzheimer's disease].
    García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
    Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of Alzheimer's disease].
    Bombois S; Lebert F; Vellas B; Pasquier F
    Rev Prat; 2005 Nov; 55(17):1913-9. PubMed ID: 16396232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients.
    Babiloni C; Del Percio C; Bordet R; Bourriez JL; Bentivoglio M; Payoux P; Derambure P; Dix S; Infarinato F; Lizio R; Triggiani AI; Richardson JC; Rossini PM
    Clin Neurophysiol; 2013 May; 124(5):837-50. PubMed ID: 23098644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
    Shemer I; Holmgren C; Min R; Fülöp L; Zilberter M; Sousa KM; Farkas T; Härtig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T
    Eur J Neurosci; 2006 Apr; 23(8):2035-47. PubMed ID: 16630051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?
    Benzi G; Moretti A
    Eur J Pharmacol; 1998 Apr; 346(1):1-13. PubMed ID: 9617746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
    Zemek F; Drtinova L; Nepovimova E; Sepsova V; Korabecny J; Klimes J; Kuca K
    Expert Opin Drug Saf; 2014 Jun; 13(6):759-74. PubMed ID: 24845946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alzheimer's disease. Arresting memory decline.
    Robbins TW
    Nature; 1988 Nov; 336(6196):207-8. PubMed ID: 2848195
    [No Abstract]   [Full Text] [Related]  

  • 33. Severe Alzheimer's disease: treatment effects on function and care requirements.
    Kerwin D; Claus TH
    J Am Med Dir Assoc; 2011 Feb; 12(2):99-104. PubMed ID: 21266285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic treatment of Alzheimer's disease: an update.
    DeLaGarza VW
    Am Fam Physician; 2003 Oct; 68(7):1365-72. PubMed ID: 14567491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Manipulation of the cholinergic system.
    Geroldi C; Bianchetti A; Trabucchi M
    Funct Neurol; 1997; 12(3-4):187-91. PubMed ID: 9218975
    [No Abstract]   [Full Text] [Related]  

  • 36. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors.
    Shah AA; Dar TA; Dar PA; Ganie SA; Kamal MA
    Curr Drug Metab; 2017; 18(2):96-111. PubMed ID: 27890007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neurotransmitters in Alzheimer's disease].
    Manzano-Palomo S; De la Morena-Vicente MA; Barquero MS
    Rev Neurol; 2006 Mar 16-31; 42(6):350-3. PubMed ID: 16575771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
    da Silva CH; Campo VL; Carvalho I; Taft CA
    J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.